StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$27.87−1.17 (-4.03%)

Close on Nov 16, 2026Market cap $4.45BP/E –Yield –

Adaptive Biotechnologies cash

Cash and short-term investments held at the end of each period.

Adaptive Biotechnologies's cash was $344.26M at Jun 30, 2026. For fiscal 2025 it was $226.98M, up 2.1% from the year before. The highest annual figure on record is $688.27M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$226.98M+2.1%
FY2024Dec 31, 2024$222.29M-35.8%
FY2023Dec 31, 2023$346.40M-30.5%
FY2022Dec 31, 2022$498.20M+41.1%
FY2021Dec 31, 2021$353.06M-48.7%
FY2020Dec 31, 2020$688.27M+19.3%
FY2019Dec 31, 2019$576.87M+249.6%
FY2018Dec 31, 2018$165.02M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$344.26M+74.0%
Q1 FY2026Mar 31, 2026$218.33M+12.9%
Q4 FY2025Dec 31, 2025$226.98M+2.1%
Q3 FY2025Sep 30, 2025$212.77M-12.6%
Q2 FY2025Jun 30, 2025$197.87M-32.2%
Q1 FY2025Mar 31, 2025$193.42M-37.4%
Q4 FY2024Dec 31, 2024$222.29M-35.8%
Q3 FY2024Sep 30, 2024$243.33M-34.4%
Q2 FY2024Jun 30, 2024$291.88M-30.0%
Q1 FY2024Mar 31, 2024$308.87M-29.9%
Q4 FY2023Dec 31, 2023$346.40M-30.5%
Q3 FY2023Sep 30, 2023$371.13M-27.0%
Q2 FY2023Jun 30, 2023$417.23M+8.7%
Q1 FY2023Mar 31, 2023$440.70M+21.2%
Q4 FY2022Dec 31, 2022$498.20M+41.1%
Q3 FY2022Sep 30, 2022$508.08M+22.4%
Q2 FY2022Jun 30, 2022$383.74M-35.9%
Q1 FY2022Mar 31, 2022$363.56M-49.1%
Q4 FY2021Dec 31, 2021$353.06M-48.7%
Q3 FY2021Sep 30, 2021$415.04M-50.3%
Q2 FY2021Jun 30, 2021$598.41M+4.9%
Q1 FY2021Mar 31, 2021$714.26M+28.7%
Q4 FY2020Dec 31, 2020$688.27M+19.3%
Q3 FY2020Sep 30, 2020$835.08M+45.6%
Q2 FY2020Jun 30, 2020$570.38M+34.8%
Q1 FY2020Mar 31, 2020$555.17M+236.4%
Q4 FY2019Dec 31, 2019$576.87M–
Q3 FY2019Sep 30, 2019$573.43M–
Q2 FY2019Jun 30, 2019$423.00M–
Q4 FY2018Dec 31, 2018$165.02M–

More Adaptive Biotechnologies figures

See a number that looks wrong?